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Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) agonists are commonly used to
treat cardiovascular diseases, and are reported to have several effects on cardiovascular function
that may be due to PPARγ-independent signaling events. Select angiotensin receptor blockers
(ARBs) interact with and modulate PPARγ activity, thus we hypothesized that a PPARγ agonist
may exert physiologic effects via the angiotensin II type 1A receptor (AT1AR). In AT1ARoverexpressing HEK 293 cells, both angiotensin II (Ang II) and the PPARγ agonist troglitazone
(Trog) enhanced AT1AR internalization and recruitment of endogenous β-arrestin1/2 (βarr1/2) to
the AT1AR. A fluorescence assay to measure diacylglycerol (DAG) accumulation showed that
although Ang II induced AT1AR-Gq protein-mediated DAG accumulation, Trog had no impact
on DAG generation. Trog-mediated recruitment of βarr1/2 was selective to AT1AR as the
response was prevented by an ARB and Trog-mediated βarr1/2 recruitment to β1-adrenergic
receptor (β1AR) was not observed. In isolated mouse cardiomyocytes, Trog increased both %
and rate of cell shortening to a similar extent as Ang II, effects which were blocked with an
ARB. Additionally, these effects were found to be βarr2-dependent, as cardiomyocytes isolated
from βarr2-KO mice showed blunted contractile responses to Trog. These findings show for the
first time that the PPARγ agonist Trog acts at the AT1AR to simultaneously block Gq protein
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activation and induce the recruitment of βarr1/2, which leads to an increase in cardiomyocyte
contractility.
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Introduction
Angiotensin II (Ang II)-mediated activation of the angiotensin type 1A receptor (AT1AR),
a member of the seven-transmembrane receptor (7TMR) family, leads to the initiation of both Gq
protein-dependent and -independent signaling cascades. Gq protein-dependent signaling involves
2nd messenger generation (e.g. diacylglycerol (DAG) accumulation), ultimately leading to a
hypertrophic response that can be maladaptive over time, but that can be attenuated via the use of
angiotensin receptor blockers (ARBs) [1; 2]. G protein-independent signaling involves
recruitment of β-arrestins 1 and/or 2 (βarr1/2) [3], multifunctional scaffold proteins that are
involved in numerous cell signaling events including initiation of receptor internalization,
activation of protein kinase and anti-apoptotic cascades and transactivation of epidermal growth
factor receptor [3; 4; 5]. β-arrestin-dependent signaling has been shown to be both
physiologically relevant and beneficial in the cardiovascular system. In cardiomyocytes, βarrestin signaling mediates protection against chronic sympathetic stimulation [6] and increases
contractility in response to AT1AR stimulation [7]. Additionally, β-arrestin signaling has been
shown to activate anti-apoptotic pathways downstream of AT1AR in vascular smooth muscle
cells [5]. Thus, an agent that acts selectively at the AT1AR to induce beneficial β-arrestin
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signaling without increasing detrimental Gq protein activity could effective in the treatment of
cardiovascular disorders.
Recent studies have shown that synthetic agonists for the transcription factor peroxisome
proliferator-activated receptor γ (PPARγ) oppose Ang II-mediated effects, reducing the
hypertrophic response of cardiomyocytes to administration of Ang II as well as decreasing Ang
II-mediated signaling in blood vessels and subsequent development of hypertension [8; 9; 10;
11]. Synthetic agonists for PPARγ are typically used in the treatment of Type II diabetes to
increase insulin sensitivity [12]. These agents have been shown experimentally and clinically to
improve cardiovascular function via increased vascular reactivity and cardiac function, decreased
inflammation and reduced visceral fat storage (as reviewed in [13]).

The mechanisms by which

PPARγ agonists oppose Ang II-mediated signaling are not fully understood, but may be
independent of PPARγ itself. In fact, PPARγ agonists such as troglitazone (Trog) have been
shown to induce acute intracellular signaling responses independent of the effects of PPARγ on
transcriptional processes, though a role for 7TMRs in mediating these responses has not been
explored [14; 15].
While PPARγ agonists have been shown to oppose Ang II signaling, a subset of
angiotensin receptor blockers (ARBs) have been shown to be selective PPARγ modulators
(SPARRMs), increasing gene transcription and modulating metabolic pathways to reduce
glucose and triglyceride levels and increase insulin sensitivity [16; 17; 18]. Since PPARγ
agonists can induce PPARγ-independent signaling, and select ARBs can activate PPARγ, we
tested the hypothesis that PPARγ agonists activate AT1AR signaling. Here, we show that Trog
stimulates the AT1AR to induce endogenous βarr1/2 recruitment and AT1AR internalization
without Gq protein activation. Moreover, cardiomyocyte contractility is increased in response to
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Trog, an effect that is sensitive to both an ARB and βarr2 expression, indicating that activation of
AT1AR-β-arrestin-mediated signaling is a mechanism by which PPARγ agonists can induce
PPARγ-independent physiologic effects.

Materials and Methods
Materials. HEK 293 cells stably expressing hemagglutinin-tagged AT1AR (HA-AT1AR cells),
the plasmid construct for monomeric cyan fluorescent protein (mCFP)/mYFP-tagged
diacylglycerol reporter (DAGR) and βarr2 knockout mice were kindly provided by Dr. RJ
Lefkowitz (Duke University Medical Center). Troglitazone (Trog) was obtained from
Calbiochem (San Diego, CA). Ang II, isoproterenol and losartan were purchased from SigmaAldrich (St. Louis, MO).

Cell culture and pharmacological treatment. HEK 293 cells stably expressing FLAG-tagged
β1-adrenergic receptor (FLAG-β1AR cells) and HA-AT1AR cells were maintained in MEM
supplemented with 10% FBS and 1% pen/strep at 37°C. Cells were serum-starved for 1hr prior
to drug treatments outlined in figure legends.

Fluorescent microscopy. HA-AT1AR cells were seeded into 35mm glass-bottom confocal
dishes (MatTek Corporation, MA) coated with 10 µg/mL collagen (Sigma-Aldrich). After 5 min
stimulation, cells were fixed with 4% paraformaldehyde/PBS for 20 min and permeabolized for 5
min with ice-cold 0.2% Triton-X 100 in PBS. Cells were blocked for 1hr and all antibodies were
diluted in 0.1% BSA in PBS. HA-AT1AR was visualized using monoclonal anti-HA clone HA-7
(Sigma-Aldrich) at 1:1,000 overnight, 4ْC, followed by goat anti-mouse IgG, Dylight594
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(Thermo Scientific, Rockford IL) at 1:1000 for 1hr. Samples were imaged using a Leica
DMI6000B inverted microscope with the Leica DFC360 FX 1.4-megapixel monochrome digital
camera. This system was controlled by and deconvolution carried out using Leica AF6000
software. Each condition was performed independently 3 times.

Chemical crosslinking and immunoprecipitation. Crosslinking was performed as previously
described [19]. Immunoprecipitation (IP) of samples was performed using 200 to 500 µg protein
and overnight incubation at 4°C with 25 µL of monoclonal anti-HA agarose or anti-FLAG M2
agarose (Sigma-Alrich). βarr1/2 recruitment was normalized to total βarr1/2 levels and amount
of immunoprecipitated HA-AT1AR or FLAG-β1AR.

Immunoblotting. Following drug treatment, cells were rinsed in ice-cold PBS then collected
and lysed in buffer containing 1% NP40, 20mM Tris, pH 7.4, 137mM NaCl, 100µg/mL PMSF,
10% Glycerol, 10mM NaF, 0.36mg/mL Na3VO4 and EDTA-free HALT protease inhibitor
cocktail (Thermo Scientific, Rockford, IL). Protein estimation was carried using Pierce 660nm
Protein Assay Reagent (Thermo Scientific), and immunoblotting of samples performed as
previously described [19]. The LI-COR biosciences Odyssey system was used for detection of
immunoblots using anti-β-arrestin1/2 (D24H9) at 1:5,000 (Cell Signaling Technology, Danvers,
MA) and anti-FLAG M2 at 1:10,000 (Sigma-Aldrich). IRDye800 conjugated anti-HA epitope
tag was used at 1:20,000 (Rockland, Gilbertsville, PA). Non-conjugated primary antibodies
were detected with IRDye680 Donkey anti-rabbit IgG (H+L) at 1:5,000 in Odyssey Blocking
Buffer (LI-COR Biosciences, Lincoln, NE).
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DAGR assay. HA-AT1AR cells transfected with DAGR were seeded into 35mm glass-bottom
confocal dishes (MatTek Corporation, MA) coated with 10 µg/mL fibronectin. Prior to assay,
cells were rinsed and incubated in buffer containing 125mM NaCl, 5mM KCl, 1.5mM MgCl2,
1.5mM CaCl2, 10mM glucose, 0.2% BSA, 10mM HEPES, pH 7.4. Cells were stimulated with
drugs and underwent fluorescence resonance energy transfer (FRET) analysis as described
previously [20], with quantification of the DAGR ratio over time calculated as FRET
intensity/mCFP intensity, normalized to baseline.

Cardiomyocyte Contractility
Mice used in these studies were C57BL/6 mice and βarr2 knockout mice (described previously,
[7; 21]), 3-6 months old and 25-40g. 10-15 cardiomyocytes were used per treatment per heart.
Animals were handled according to approved protocols and animal welfare regulations of the
Institutional Review Board at Duke University Medical Center. Myocyte isolation, visualization
and analysis were carried out as previously described [22; 23].

Statistical Analysis
Data are presented as mean±s.e.m. All statistical analyses were performed using One-way
ANOVA with Tukey’s multiple comparisons test via Prism 5.0 software.

Results
Troglitazone induces AT1AR internalization and β-arrestin recruitment without activation
of Gq protein.
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To determine if a PPARγ agonist can stimulate the AT1AR, we performed several assays
to explore different facets of receptor activation. A common response to 7TMR stimulation is
internalization, thus we initially aimed to determine if the PPARγ agonist Trog induces AT1AR
internalization. HA-AT1AR cells were treated with Trog or Ang II, as a positive control for
internalization, and HA-AT1AR puncta formation was assessed via immunofluorescence
analysis. HA-AT1AR puncta formation was increased in response to both Ang II and Trog (Fig.
1, panels 2 and 3 arrowheads), indicating that the PPARγ agonist stimulates AT1AR
internalization.
Downstream effects of AT1AR activation are mediated by both Gq protein-dependent and
βarr1/2-dependent signaling [24]. Gq protein activity can be assessed using DAGR, a fluorescent
biosensor containing a diacylglycerol (DAG) binding domain flanked by mCFP and mYFP that
produces an increase in intermolecular FRET in response to DAG generation at the membrane
[20]. HA-AT1AR cells expressing DAGR underwent stimulation with Trog, or Ang II as a
positive control for Gq protein activation. In response to Ang II, the FRET ratio increased
sharply, indicating a rapid generation of DAG at the membrane (Fig. 2A) however stimulation
with the same concentration of Trog (100µM) that induced AT1AR internalization did not
increase DAG production, as shown by an unaltered FRET ratio. These results indicate that,
while Trog induces AT1AR internalization, it does not stimulate AT1AR-mediated Gq protein
activity.
Since βarr1/2 recruitment to activated AT1ARs is required for receptor internalization
[24], we tested whether Trog acts to recruit endogenous βarr1/2 to the AT1AR. HA-AT1AR cells
were stimulated with increasing concentrations of Trog, or Ang II as a positive control for
βarr1/2 recruitment, and underwent chemical crosslinking, immunoprecipitation of HA-AT1AR
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and immunoblotting analysis. Trog and Ang II each significantly increased βarr1/2 recruitment
to HA-AT1AR in a concentration-dependent manner (Fig. 2B). Concentrations of Ang II in the
low nanomolar range (5-10nM) produced equivalent βarr1/2 recruitment elicited by
concentrations of Trog in the high micromolar range (50-100µM), concentrations shown to
induce AT1AR internalization (Fig. 1) and previously shown by others to mediate PPARγindependent effects [14; 25]. These data show that while Trog has no effect on AT1AR-coupled
Gq protein activity, it does induce βarr1/2 recruitment to the AT1AR and promote receptor
internalization.
Troglitazone-mediated β-arrestin recruitment is selective for the AT1AR
Trog-mediated βarr1/2 recruitment to the AT1AR suggests that Trog acts at the AT1AR
itself to stimulate the response, thus we tested whether β-arrestin recruitment could be blocked
with an ARB. Using matched submaximal concentrations of Trog (50µM) and Ang II (5nM) for
βarr1/2 recruitment, the ability of the ARB, losartan (Los), to block Trog-mediated βarr1/2
recruitment to AT1AR was assessed via immunoprecipitation. As a positive control for Losmediated inhibition of the AT1AR, Ang II-mediated βarr1/2 recruitment to HA-AT1AR was
prevented by Los pretreatment (Fig. 3A). Similarly, Trog-mediated βarr1/2 recruitment to HAAT1AR was ablated by pretreatment with Los. These results indicate that Trog acts directly at
the AT1AR to induce βarr1/2 recruitment, an effect that can be surmounted with an ARB.
To investigate whether βarr1/2 recruitment in response to Trog is selective to the AT1AR
or is a nonselective response to high concentrations of Trog at 7TMRs in general, we tested the
ability of Trog to induce recruitment of βarr1/2 to the β1-adrenergic receptor (β1AR). FLAGβ1AR cells were stimulated with the highest concentration of Trog (100µM) shown to induce
βarr1/2 recruitment to the AT1AR, or isoproterenol (ISO, 1µM) as a positive control for βarr1/2
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recruitment to the β1AR. While ISO stimulation induced a significant increase in βarr1/2
recruitment to the β1AR, Trog was unable to promote β-arrestin recruitment to the β1AR (Fig.
3B), indicating that Trog-induced βarr1/2 recruitment is selective for the AT1AR.

Troglitazone increases cardiomyocyte contractility via the AT1AR in a β-arrestindependent manner
To determine if a PPARγ agonist induces a physiologic effect mediated by AT1AR
signaling, we measured the effect of Trog on the contractility of freshly isolated murine
cardiomyocytes. Treatment of wild-type cardiomyocytes with concentrations of Trog that were
shown to induce βarr1/2 recruitment to AT1AR (50-100µM, Fig. 2B) resulted in a significant
increase in both the percentage and rate of cell shortening (Fig. 4A, black bars). These Trogmediated effects on contractility were statistically indistinguishable from those of Ang II.
Importantly, the Trog-mediated increase in cardiomyocyte contractility was blocked by
pretreatment with an ARB (valsartan, Val). These results confirm our observation that Trog acts
via the AT1AR and indicate that this interaction is capable of mediating a physiologic increase in
cardiomyocyte contractility.
Since βarr2 plays a role in AT1AR-mediated myocyte contractility [7], we tested whether
βarr2 signaling is required for Trog-mediated effects on myocyte contractility. Cardiomyocytes
isolated from βarr2 knockout mice (βarr2-KO) exhibited blunted cell shortening responses to
both Ang II and Trog stimulation that were not statistically different from untreated cells (Fig.
4A, grey bars). To ensure that βarr2-KO cardiomyocytes were responsive to a contractile
stimulus, they were treated with ISO, which produced a significant increase in contractile
response. Comparison of the contractility increases achieved in wild-type versus βarr2-KO
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cardiomyocytes revealed a significantly diminished response to both Ang II and Trog in the
absence of β-arr2 (Fig. 4B). Thus, βarr2 is a key mediator of Trog-induced cardiomyocyte
contractility.

Discussion
In this study, we show that the PPARγ agonist Trog acts at the AT1AR to induce AT1AR
internalization and ARB-sensitive recruitment of βarr1/2, in the absence of Gq protein activation.
Moreover, we show that Trog increases cardiomyocyte contractility in an ARB-sensitive manner
and is, at least partially, β-arrestin2-dependent. Although PPARγ agonists classically activate
PPARγ to mediate gene transcription, it has also been shown that these agents can exert PPARγindependent cell signaling processes [14; 15; 26]. Our observation that a PPARγ agonist acts at
the AT1AR to rapidly recruit βarr1/2 suggests a lack of role for PPARγ-mediated transcriptional
events in this process. With regard to cardiomyocyte function, our data highlights the ability of
Trog to induce an acute physiologic response via AT1AR signaling, increasing cardiomyocyte
contractility. These data, coupled with the ARB-sensitive nature of Trog-mediated AT1AR-βarrestin signaling, suggest that Trog-mediated effects at the level of AT1AR are independent of
PPARγ activation.
PPARγ agonists, including Trog and ciglitazone, have been previously reported to exert
off-target effects, influencing intracellular processes independent of PPARγ activation in
different cell lines and tissue [14; 15; 26]. One of these processes involved alterations in
intracellular and/or extracellular Ca2+-handling, dependent upon the PPARγ agonist, though a
role for AT1AR in this process was not explored [14]. Such effects on Ca2+-handling may
explain our observation that a portion of the Trog-induced cardiomyocyte contractility was
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βarr2-independent, as approximately half the contractile response remained in the absence of
βarr2 (Fig. 4C). In our study, we show Trog-mediated AT1AR effects are independent of Gq
protein activation but dependent on β-arrestin recruitment. The ability of a 7TMR to utilize βarrestin to exert downstream signaling is now being recognized as a mechanism to stimulate
physiologic effects and accumulating data suggests that β-arrestin-mediated signaling opposes
detrimental G protein-mediated activity to confer beneficial cellular effects [3; 6; 27].
The ability of ligands to stabilize receptors in certain conformations that activate
particular signaling pathways but not others has been increasingly explored [28; 29]. [Sar1, Ile4,
Ile8]-Ang (SII) was shown to act at the AT1AR to preferentially enhance β-arrestin-mediated
signaling with no effect on Gq protein activity and has been suggested to be more
cardioprotective than conventional ARBs that prevent both G protein- and β-arrestin-dependent
signaling [7; 19; 30]. Our study shows that the PPARγ agonist Trog acts similarly to SII by
preferentially enhancing β-arrestin recruitment to AT1AR and subsequent cardiomyocyte
contractility. We postulate that PPARγ-mediated activation of AT1AR-β-arrestin signaling may
in part provide an explanation for the cardioprotective effects of PPARγ agonists reported in the
literature [8; 9; 10]. An additional benefit of PPARγ agonist action at the AT1AR may be the
lack of potentially detrimental Gq protein-mediated signaling, especially under conditions of
heightened Ang II stimulation, such as the development of hypertension. Others have suggested
that the use of SPARRMs to simultaneously block AT1AR activation and induce PPARγ activity
would be clinically more beneficial than conventional PPARγ agonists by exerting both
antihypertensive and antidiabetic effects [17; 18]. Alternatively, using Trog as an example, we
suggest PPARγ agonists may show enhanced clinical usefulness by simultaneously inducing

11

beneficial PPARγ- and AT1AR-βarrestin-mediated effects without a concomitant increase in
potentially detrimental AT1AR-Gq protein-mediated signaling.

Conclusions
Our study shows that the PPARγ agonist Trog stimulates β-arrestin recruitment to the
AT1AR and induces receptor internalization independent of Gq protein activity. Effects of
PPARγ agonists on acute cardiomyocyte function have not previously been reported, and here
we show Trog increases cardiomyocyte contractility in a βarr2-dependent manner. We propose
that a PPARγ agonist with enhanced efficiency at inducing β-arrestin recruitment to the AT1AR,
in the absence of Gq protein-mediated effects, could provide a means of potentiating the
beneficial effects of both PPARγ agonists and ARBs in the treatment of cardiovascular ailments.
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Figure 1: The PPARγ agonist troglitazone increases AT1AR internalization. HA-AT1AR
cells stimulated with Ang II (100nM, panel 2) or Trog (100µM, panel 3) for 5 min underwent
immunofluorescent analysis for HA-AT1AR localization. Ang II and Trog stimulation each
enhanced AT1AR internalization as indicated by the increased formation of HA-AT1AR-
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containing puncta (arrowheads), as compared to non-stimulated cells (NS, panel 1).
Representative images shown, n = 3 of each condition, scale bar = 10µm.

Figure 2: The PPARγ agonist troglitazone induces βarr1/2 recruitment to the AT1AR in a
Gq protein-independent manner. (A) FRET analysis was used to assess the Gq protein-
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mediated response to agonist stimulation by detecting changes in the FRET ratio of transientlytransfected DAGR in HA-AT1AR cells. Ang II (100nM) stimulation induced a rapid increase in
DAGR ratio which peaked at 90 sec, while Trog (100µM) stimulation produced no response in
DAGR ratio, n = 3 independent experiments. (B) HA-AT1AR cells were stimulated for 5 min
with Ang II (1-10nM) or Trog (10-100µM) and underwent crosslink/IP with HA-agarose gel.
βarr1/2 was recruited to HA-AT1AR in a concentration-dependent manner in response to both
Ang II and Trog, as summarized in histogram. *P<0.05, †P<0.01 and ‡ P<0.001 versus nonstimulated cells (NS), n = 6 each.

Figure 3: The PPARγ agonist troglitazone recruits β-arrestin to the AT1AR selectively. (A)
HA-AT1AR cells were stimulated with Ang II (5nM) ± Losartan (Los, 10µM) or Trog (50µM) ±
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Los (100µM) for 5 min and underwent crosslink/IP as described in Figure 2B. βarr1/2
recruitment to AT1AR was significantly increased following stimulation with either Ang II or
Trog, an effect blocked by 5 min Los pretreatment, as summarized in histogram. †P<0.01 and ‡
P<0.001, n ≥ 3 each. (B) FLAG-β1AR cells were stimulated with ISO (1µM) or Trog (100µM)
for 5 min and underwent crosslink/IP with FLAG-M2 agarose. βarr1/2 recruitment to β1AR was
significantly increased following stimulation with ISO, but not Trog, as summarized in
histogram. ‡ P<0.001 versus cells with no pharmacological treatment, n = 3 each.
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Figure 4: The PPARγ agonist troglitazone induces AT1AR-β-arrestin-dependent
cardiomyocyte contractility. (A) Isolated wild-type or βarr2-KO cardiomyocytes were fieldstimulated at 0.5 Hz basally or following treatment with Ang II (10µM), Trog (50 or 100µM),
Val (10µM) or ISO (1µM). Histograms summarize % (upper) and rate (lower) of cardiomyocyte
shortening. †P<0.001 versus cells with no pharmacological treatment, n ≥ 3 individual hearts.
(B) Comparison of the % change in contractility, relative to cells with no pharmacological
treatment, in response to Ang II (10µM) or Trog (50 or 100µM) in wild-type versus βarr2-KO
cardiomyocytes. *P<0.05 versus wild-type within corresponding treatment group.
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